S&P 500Dow JonesNASDAQ 100DAX 40MDAXSDAXTecDAXATXSMICAC 40AEXBEL 20IBEX 35
Home/SDAX/Dermapharm
Dermapharm

Dermapharm

DMP.DESDAX
37,90 €
Dividend yield2,30 %
Continuity9 yr
Dividend0,88 €
ISINDE000A2GS5D8
DiviScore
52SCOREGood
Performance19/35
Dividend Quality18/35
AGM Date
Ex-Date
29.06.2026
Payment
CAGR 3Y
-3.9%
CAGR 5Y
-14.7%

€10,000 invested in 2018 · with dividend reinvestment

+76%
End Value
17.647,86 €
Total Return
+76.5%
Annual Return
7.0% p.a.
Dividends Received
3.759,95 €

Dividend history

9 years continuous
YearAmountDividend yieldAGM dateEx-datePayment dateChange
20260,88 €29.06.2026-2.2%
20250,90 €26.06.202627.06.202501.07.20260.0%
20240,90 €26.06.202527.06.202501.07.2025+2.3%
20230,88 €27.06.202428.06.202402.07.2024-16.2%
20221,05 €14.06.202315.06.202319.06.2023-51.6%
20212,17 €01.06.202202.06.202206.06.2022+146.6%
20200,88 €23.06.202124.06.202128.06.2021+10.0%
20190,80 €19.05.202018.06.202018.07.2020+3.9%
20180,77 €06.05.201905.06.201905.07.2019

Quarterly Results

57% Beat Rate
QuarterDateEPS (Est.)EPS (Actual)Surprise
Q2 202622.06.2026-0,01 €-0,01 €
Q1 202631.03.20260,41 €0,73 €+78.0%
Q4 202503.12.20250,27 €0,45 €+66.7%
Q4 202216.11.20220,95 €0,57 €-40.0%
Q3 202207.09.20220,72 €0,29 €-59.7%
Q2 202218.05.20220,83 €0,73 €-12.1%
Q4 202116.11.20210,98 €1,13 €+15.3%
Q3 202107.09.20210,61 €0,74 €+21.3%

About Dermapharm

Dermapharm Holding SE is a leading manufacturer of branded pharmaceuticals and other healthcare products, founded in 1991 by Wilhelm Beier and headquartered in Grünwald near Munich, Germany. The company operates an integrated business model encompassing in-house product development, production, quality management, and distribution through a specialized sales force. Its primary segments include Branded pharmaceuticals, featuring over 1,300 marketing authorizations with more than 390 active pharmaceutical ingredients focused on dermatology, allergy therapy, and other key therapeutic areas where it holds market leadership, particularly in Germany; Other healthcare products, such as food supplements, herbal pharmaceuticals, cosmetics, medical devices, herbal extracts, and medicinal cannabis, bolstered by subsidiaries like Euromed S.A. in Spain and Arkopharma in France; and a Parallel import business under the axicorp brand. With production sites in Brehna near Leipzig and other locations across Europe and the United States, Dermapharm manufactures about 90% of its portfolio internally, emphasizing innovation through over 60 ongoing development projects and strategic acquisitions for international expansion into Europe, Asia, and the Americas. This structure positions it as a significant player in the European pharmaceutical market, serving prescription, over-the-counter, and consumer health needs.

IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
KGV (PE)14.28
Payout Ratio31.8%
ROE25.6%

Frequently Asked Questions

The next payment date is not yet announced.
Dermapharm has a DiviScore of 52/100. DiviScore rates dividend stocks based on price performance, dividend quality, fundamentals, and stability.
Dermapharm's current dividend yield is 2.30% based on the latest dividend.
Dermapharm (DMP.DE) is a member of SDAX. Current data including price, dividend, and DiviScore is updated daily.
DiviScore is a proprietary 100-point rating based on four pillars: Performance (35 pts), Dividend Quality (35 pts), Fundamentals (15 pts), and Stability (15 pts). It simulates a 10-year investment with automatic dividend reinvestment.